Discovery/R&D

  1. RNA Delivery Business with Liberate's Shawn Davis, Ph.D. & Walter Strapps, Ph.D. 11/8/2023

    Earlier this year, Shawn Davis, Ph.D. left a pretty comfortable position at AstraZeneca (and Amgen before that, and Milliken – and others – before that) to lead Liberate Bio. He brought along another industry notable in Merck/Intellia alumnus Walter Strapps, Ph.D., who serves as CSO at Liberate. Why'd they do it? Because RNA delivery is such a crucial step toward revolutionary genetic medicine, but it's tough science. They think they can change that.

  2. Reprogramming Human Cells With bit.bio's Mark Kotter, M.D. 2/12/2024

    The concept of programmable biology is fueling a new breed of biotech, one that requires the marriage of computational and traditional science (and both computational and traditional scientists) on the entire journey from discovery to commercial. Bit.bio is exemplary of this new breed.

  3. New Apps For AI in mRNA With Anima Biotech's Yochi Slonim 5/5/2024

    From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a leader at Tecnomatix, which sold to UGS and was acquired by Siemens. Those big deals that came on the heels of several other Yochi Slonim software startups. But Slonim's not in software development anymore.

  4. An AI Awakening With Profluent Bio's Hilary Eaton, Ph.D. 9/22/2024

    Hilary Eaton, Ph.D. was a self-described AI skeptic, particularly regarding using the tool in drug discovery. Then, a series of professional and deeply personal life events and medical discoveries put her in a position to confront that skepticism head-on. On Business of Biotech, the Chief Business Officer at ProFluent Bio shares her story and makes a pragmatic case for the transformative value of AI to biotech builders.

  5. The AAV Vector Challenge With Selecta's Dr. Carsten Brunn 1/12/2021

    The Business of Biotech kicks off our Cell & Gene Miniseries with Dr. Carsten Brunn, President & CEO at Selecta Biosciences. Guest host Erin Harris, chief editor at cellandgene.com, joins us for a discussion on Selecta's ImmTOR platform and how the company is addressing the immunogenicity of adeno-associated virus (AAV) vectors challenge faced by gene therapy companies.

  6. Improving Cardiovascular Outcomes With Immediate Therapeutics' Atul Deshpande, Ph.D. 8/27/2025

    On this week's Business Of Biotech episode, Atul Deshpande, Ph.D., CEO at Immediate Therapeutics, talks about partnering with American cities to conduct clinical trials during ambulance rides to the hospital, with the goal of preserving heart function and reducing mortality related to acute cardiovascular events, including heart attacks.

  7. How To Hire And Build A Winning Executive Team With Occam Global's Bill Holodnak 8/6/2025

    On this week's Business of Biotech episode, Bill Holodnak, Cofounder and CEO of Occam Global, a life sciences executive recruitment firm (and occasional investor), shares insights from his decades of experience pairing executives with drug development companies, and talks about the psychology of successful biotech leadership.

  8. Pioneering Antiviral Conjugates With Cidara's Dr. Jeff Stein 3/1/2021

    Cidara Therapeutics President and CEO Dr. Jeff Stein joins the Business of Biotech to discuss his career mission to battle microbial organisms and his company's development of a novel approach to producing immunotherapeutic antivirals that couple potent antivirals to a human antibody fragment. We discuss the company's manufacturing approach, which Dr. Stein anticipates yielding a low-cost alternative to standards of care in multiple antiviral indications.

  9. BoB@JPM: Support Of A Blossoming Pipeline With Sangamo's Sandy Macrae, Ph.D. 2/5/2023

    The Business of Biotech podcast took to the streets of San Francisco during the 41st Annual J.P. Morgan Healthcare Conference. This week's episode features a conversation with Sangamo Therapeutics CEO Sandy Macrae, Ph.D., who rationalizes the company's aggressive pipeline development and its decision to invest in multinational AAV and cell therapy manufacturing facilities in France and California. Dr. Macrae zeroes in on the relationship between people and processes that's enabled the company to grow to more than 500 associates working on nearly 20 cell therapy, gene therapy, and genome engineering programs. 

  10. What's A Biologic Revolution? With Vaxxinity's Mei Mei Hu, J.D. 8/8/2022

    Vaxxinity CEO Mei Mei Hu, J.D. leads a company with some lofty ambitions. The democratization of healthcare, interplanetary colonization, and development of accessible therapeutic vaccines to serve and enable both. Those big-picture visions have helped the company establish itself as a pioneer of the "third biologics revolution." On this week's Business of Biotech podcast, Mei Mei joins me to share Vaxxinity's strategy, what "democratization" and "revolution" really_mean, why traditional vaccines and biologic therapies are converging to form the "third biologic revolution," and a whole lot more.